Condition
Type2 Diabetes
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 291 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownUK Imaging Diabetes Study Seeing Diabetes ClearlyNCT05057403 · 2022-05-30
RECRUITINGBrain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)NCT05277558 · 2022-05-24
RECRUITINGEfficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes RemissionNCT05015283 · 2022-02-01
RECRUITINGSGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research PlanNCT05057806 · 2021-01-13
RECRUITINGiGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational DiabetesNCT04206748 · 2019-11-12
RECRUITINGSmall Bowel DiversionNCT06374368 · 2019-05-01
RECRUITINGPsychosocial, Environmental, and Chronic Disease Trends in Puerto RicoNCT03794531 · 2019-03-01
RECRUITINGEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)NCT03883412 · 2019-02-28
RECRUITINGA Causative Role for Amylin in Diabetic Peripheral NeuropathyNCT03481283 · 2018-02-05
RECRUITINGSTOP DIABETES - Knowledge-based SolutionsNCT03156478 · 2017-04-10
RECRUITINGDiabetes Prevention AI: Enhancing Prevention Strategies Using Personalized Nutrition and Fitness Coaching for the Next GenerationNCT07824154 · 2026-10-01
NOT_YET_RECRUITINGMobilizing Doulas to Empower Black Women in Post-partum Diabetes PreventionNCT04406792 · 2025-01-31
WITHDRAWNA Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.NCT06849843 · 2024-12-18
COMPLETEDEffectiveness of PICC Improving HBA1C and Knowledge in Diabetes Mellitus EducationNCT05106231 · 2023-05-01
COMPLETEDProtective Cooling Measures to Safeguard Elderly People From Dangerous Summer HeatNCT05274009 · 2023-05-01
UNKNOWNFirst-time Usage of SGLT2 Inhibitors in Type 2 Diabetic Patients Who Are Fasting During Ramadan: Safety and EfficacyNCT06370247 · 2023-04-25
COMPLETEDOP5-005 Using Omnipod 5 in Adults With Type 2NCT05815342 · 2023-04-11
COMPLETEDProbiotic Lysate (Postbiotic and Metabiotic) Supplementation for Type 2 Diabetes Patients (DELI_Diab Study)NCT05770076 · 2023-02-01
COMPLETEDThe Effect of Tele-Nursing Based Motivational Interviewing in Individuals With Type 2 Diabetes:RCTNCT05628259 · 2023-02-01
COMPLETEDFeasibility of Yoga for Type-2 DiabetesNCT04982640 · 2022-10-24
COMPLETEDEffects of VLCD and Bariatric Surgery in Patients With Type 2 DiabetesNCT05092399 · 2022-07-01
COMPLETEDA Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASHNCT03970031 · 2022-06-01
UNKNOWNA Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or BothNCT05260021 · 2022-04-13
COMPLETEDEvaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.NCT05262257 · 2022-04-01
UNKNOWNThe Mobile Lifestyle Intervention for Food and Exercise StudyNCT05176847 · 2022-03-01
COMPLETEDCoronary Artery Calcium-guided Primary Prevention of Major Coronary Heart Disease in Asymptomatic DiabetesNCT05267990 · 2022-03-01
ENROLLING_BY_INVITATIONDiabetic Retinopathy Screening in General PracticeNCT05276778 · 2022-02-28
COMPLETEDAssociation of Bisphenol A,Paraben Exposure and Type 2 DiabetesNCT05177250 · 2022-02-20
UNKNOWNThe Effect of Hypoxia on Type 2 Diabetes and Weight LossNCT05147116 · 2022-02-17
COMPLETEDSemaglutide as an Adjunct to Dieting in the Treatment of Type 2 DiabetesNCT04854083 · 2022-02-17
UNKNOWNAdvancing DSME/S and COVID-19 Prevention and Protection Through "emPOWERed to Change" ProgramNCT04993326 · 2022-01-10
WITHDRAWNEffects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 DiabetesNCT05160272 · 2022-01-07
COMPLETEDComparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 DiabetesNCT05194592 · 2022-01-07
UNKNOWNEfficacy Assessment of Chinese Herbal Medicine Jiangtang Tiaozhi Recipe Treating Participants With Glucose and Lipid Metabolism DisturbancesNCT04623567 · 2021-12-22
UNKNOWNThe Attenuating Effect of Soluble Fiber Consumption on Postprandial Glycemia in HumansNCT05349916 · 2021-12-07
COMPLETEDEfficacy and Safety of Recombinant Human Insulin Patch ZJSRM2021NCT05089942 · 2021-12-01
UNKNOWNPersonalized Exercise Therapy and Self-management Support for Patients With MultimorbidityNCT04645732 · 2021-11-01
COMPLETEDElectronic Frailty Index (eFI)Cacious-Diabetes CareNCT05047237 · 2021-10-29
COMPLETEDEvaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes MellitusNCT05631431 · 2021-10-15
UNKNOWNA Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)NCT04998032 · 2021-10-12
COMPLETEDPersonalized Follow-up Program in the Type 2 Diabetes PreventionNCT04907760 · 2021-10-10
NOT_YET_RECRUITINGDate Fruit Effects in Type 2 DiabetesNCT04616066 · 2021-10-10
COMPLETEDUse of an Investigational Digital Therapeutic in Patients With Type 2 DiabetesNCT05094401 · 2021-10-04
TERMINATEDReducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical ActivityNCT04717050 · 2021-09-23
COMPLETEDType 2 Diabetes With Antiplatelet DrugsNCT05053828 · 2021-09-20
COMPLETEDTangningtongluo Tablet in the Treatment of Non-proliferative Diabetic RetinopathyNCT05007262 · 2021-08-31
UNKNOWNPrevention With the Health and Lifestyle ToolNCT05006508 · 2021-08-16
ACTIVE_NOT_RECRUITINGA Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)NCT04994288 · 2021-08-03
COMPLETEDEvaluation of the Efficacy and Safety of Curalin as Add-On Therapy in Adults With Type 2 Diabetes MellitusNCT05439473 · 2021-08-03
COMPLETEDComparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyNCT05220917 · 2021-08-01
ACTIVE_NOT_RECRUITINGInfluence of Preprandial Metformin Administration on Carbohydrate AbsorptionNCT04018105 · 2021-07-28
COMPLETEDThe Effect of IMB Model-Based Diabetes Education and Motivational Interviewing on Care Outcomes in Adults With T2DMNCT05030844 · 2021-07-14
COMPLETEDMetabolism of Low Carbohydrate and Ketogenic DietNCT05071287 · 2021-06-03
COMPLETEDDietary Approaches to Stop Hypertension for DiabetesNCT04286555 · 2021-06-02
COMPLETEDA Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinNCT04885712 · 2021-05-28
COMPLETEDChronic Passive Heating in Individuals With T2DMNCT04858321 · 2021-05-24
COMPLETEDNAFLD Primary CareNCT04918732 · 2021-05-05
UNKNOWNCardiovascular Risk and Functional Responses From Dancing at Home in the Elderly With and Without Type 2 DiabetesNCT04840368 · 2021-05-03
UNKNOWNEfficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus PatientsNCT06329674 · 2021-04-27
COMPLETEDContinuous Glucose Monitoring Initiation at Hospital DischargeNCT04854135 · 2021-04-13
TERMINATEDCommon interventions
PlaceboDRUG17DapagliflozinDRUG8PlaceboDIETARY_SUPPLEMENT7PlaceboOTHER5CKD-501 0.5mgDRUG3DPP-4 inhibitorDRUG3MetforminDRUG3SGLT2 inhibitorDRUG3Activity TrackerDEVICE2Balanced diet high in Slowly Digestible StarchOTHER2Balanced diet low in Slowly Digestible StarchOTHER2Bariatric SurgeryPROCEDURE2CoachingBEHAVIORAL2Continuous Glucose Monitor (CGM)DEVICE2ControlBEHAVIORAL2CuralinDIETARY_SUPPLEMENT2DA-1229_01(A), Sugamet SR Tab 5/1000mg®DRUG2Dapagliflozin 10mgDRUG2Digital Storytelling InterventionBEHAVIORAL2EmpagliflozinDRUG2Empagliflozin 25 MGDRUG2EvogliptinDRUG2EvolocumabDRUG2FibroScanDIAGNOSTIC_TEST2Lifestyle interventionBEHAVIORAL2
Leading sponsors
Dong-A ST Co., Ltd.
7
Nanjing First Hospital, Nanjing Medical University
6
Bogomolets National Medical University
5
Chong Kun Dang Pharmaceutical
4
Mayo Clinic
4
University Hospital, Gentofte, Copenhagen
4
Copenhagen University Hospital, Rigshospitalet
3
India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
3
NYU Langone Health
3
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
3
University of Southern Denmark
3
Arizona State University
2
Brigham and Women's Hospital
2
Cairo University
2
Colorado State University
2
Trial status mix
COMPLETED190
UNKNOWN57
TERMINATED15
RECRUITING10
WITHDRAWN8
ACTIVE_NOT_RECRUITING6
ENROLLING_BY_INVITATION3
NOT_YET_RECRUITING2
Phase mix
NA155
PHASE430
PHASE220
PHASE319
PHASE112
EARLY_PHASE15
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.